Life science deals financing has raised $32.5 million in the final closing of a private placement of common stock and warrants to purchase common stock for Celator.
Proceeds totaling $39.3 million, including $6.8 million from prior closings, have been raised in this life science deals financing and will support the late-stage clinical development of the Company's lead investigational product, CPX-351 Liposome Injection.
The product is used in the Oncology area for the treatment of Acute Myelogenous Leukemia.
This life science deals financing is expected to fully fund the Company's currently enrolling Phase 3 clinical study as first-line therapy in patients, 60-75 years of age, with secondary acute myeloid leukemia.
Daily news stories
For further deal information visit Current Agreements (subscription required)
Report: Leukemia Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity